Background: This study was designed to compare the benefits of intramuscular progesterone, 100 mg daily, and cyclogest suppository, 400 mg BID, to support luteal phase in IVF cycle.
Materials and methods: In this Clinical Trial study 162 patients, between 20-40 years, were selected for rapid Zift cycles. Seventy seven cases used 400 mg cyclogest suppository BID and 88 used 100 mg daily intramuscular progestron to support luteal phase. Age, duration of infertility, number of follicles and number of embryos were the variables which were assessed. Pregnancy rate and abortion rate were also compared between the two groups who underwent the treatment.
Results: Frequency of chemical pregnancy (positive β-HCG) was 27.3% in cyclogest and 30.6% in intramuscular progesterone group and there was no significant difference between two groups (NS). Clinical pregnancy, according to sonography findings on 5th week, was seen in 22.1% of cyclogest and 27.1% of intramuscular progesterone group (NS). Frequency of ongoing pregnancy was 15.6% in cyclogest and 18.8% in intramuscular progesterone group and there was no significant difference between two groups (NS).
Conclusion: In this study, the frequency of pregnancy, including chemical and clinical pregnancy, in intramuscular progesterone group was more than cyclogest group, whereas there was no significant statistical difference between two groups with regard to the number of cases. Therefore, we need to assess the study with more cases.